|
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial
|
Aug 2020
|
Lancet Hematology
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
|
Mar 2016
|
Lancet Oncol
|
myelodysplastic syndromes (MDS)
|
|
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
|
Sep 2017
|
Lancet Oncol
|
myelodysplastic syndromes (MDS)
|
|
Defeating anaemia in myelodysplastic syndromes: another step forward
|
Sep 2017
|
Lancet Oncol
|
myelodysplastic syndromes (MDS)
|
|
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study
|
Sep 2015
|
Lancet Oncol.
|
myelodysplastic syndromes (MDS)
|
|
Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment
|
May 2015
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials
|
Feb 2012
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
The Race for Survival in Myelodysplastic Syndromes
|
Sep 2012
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine
|
Sep 2014
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Patients with Myelodysplastic Syndromes Treated with Azacitidine in Clinical Practice: The AVIDA® Registry
|
Jun 2014
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
